Cambridge, United Kingdom
STORM Therapeutics Limited, founded in 2015 and based in the United Kingdom, is a pioneering biotechnology firm uniquely positioned in the realm of RNA modification. With the slogan, "Harnessing the power of RNA modification," the company focuses on creating breakthrough therapies targeting RNA modifying enzymes (RME) for oncology and other diseases.
There are over 150 RNA modifications and approximately 300 RNA modifying enzymes available as novel therapeutic targets. Leveraging its first-mover advantage, STORM has established a drug discovery and RNA analytics platform, identifying novel targets and developing a proprietary pipeline of first-in-class small-molecule drug candidates. Notably, their METTL3 inhibitor (STC-15) signifies the first RME inhibitor to reach human clinical evaluation.
Recently, STORM raised a $56.00M Series C investment on April 16, 2026, with participation from prominent investors, including M Ventures, Pfizer Ventures, and Taiho Ventures LLC, among others. Their R&D team operates out of state-of-the-art labs on the Babraham Research Campus, complemented by partnerships with esteemed CROs like Evotec, ensuring a cost-efficient and adaptable operational model.
